ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3128-Box-Hill-Box-Hill-Hospital-Eastern-Health
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
45
trial(s) found.
NCT07300943
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors (
CLIO-8221-001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase/ATR inhibitor payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07284849
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (
INCA033890-303
)
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07218809
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (
TREVI-OC-01
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07218380
Advanced
Phase 3
Recruiting
FORAGER-2
: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
FGFR3 inhibitor
anti-NECTIN4 antibody-drug conjugate
anti-PD-1 monoclonal antibody
placebo
Bladder cancer
Cancer
Carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07214779
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (
MAESTRA-2
)
CDK2 inhibitor
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06830850
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (
HRS-5041-103
)
AR PROTAC degrader
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
2024-515593-27-00--BGB-11417-302
)
BTK inhibitor
Bcl2 inhibitor
placebo
Mantle cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06697301
Advanced
Phase 2 / Phase 3
Recruiting
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006) (
EIK1001-006
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Melanoma
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06679101
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (
DREAMM-10
)
anti-BCMA-immunoconjugate
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT06594926
Curative
Phase 2
Recruiting
Evaluating the Efficacy of Bipolar Androgen Therapy in Extending Metastasis-free Survival in Patients With M0 Castrate-resistant Prostate Cancer With PSA Progression But Not Radiological or Clinical Progression on Darolutamide (
WOMBAT
)
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor (
2024-515689-15-01--18877
)
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06578247
Haem
Phase 3
Recruiting
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (
QuANTUM-WILD
)
FLT3 inhibitor
KIT inhibitor
placebo
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT06561386
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1% (
RELATIVITY1093
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4120 - Greenslopes - Greenslopes Private Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06534983
Curative
Phase 2
Recruiting
A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma (
IMCODE004
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
personalized cancer vaccine
Urothelial carcinoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06499285
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) (
2024-516009-22-00--KER-050-D301
)
modified ActRIIA ligand trap protein
placebo
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06456463
Haem
Phase 2
Recruiting
A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (
TRILLIUM
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
IL-3 diphtheria toxin fusion protein
antimetabolite
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06284317
Curative
Phase 3
Recruiting
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC (
ADOPT-lung
)
anti-PD-L1 monoclonal antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06208150
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide (
MonumenTAL-6
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
VIC
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
NCT06158854
Haem
Phase 1
Recruiting
An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis (
2023-503429-20-00--M24-209
)
bispecific T-cell engager,BCMA-targeting
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05951049
Haem
Phase 2
Recruiting
A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02 (
AT02-003
)
pan-amyloid-binding peptide fusion immunoglobulin
AL amyloidosis
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NCT05827016
Haem
Phase 3
Recruiting
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (
2022-501515-14--IM048-022
)
CELMoD agent
immunomodulatory imide drug
Multiple myeloma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05694936
Advanced
Phase 2
Recruiting
A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (
VADER
Study).
HDAC inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05611931
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (
XPORT-EC-042
)
XPO1 inhibitor
placebo
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - ICON Cancer Care
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.9016 - Dunedin - Dunedin Hospital
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05303532
Advanced
Phase 3
Enrolling by invitation
ROSY-D
: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
anti-PD-L1 monoclonal antibody
Cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT04920617
Haem
Phase 2
Recruiting
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
VITALIZE
)
alkylating agent
anti-PD-1 monoclonal antibody
cell therapy,T-cell immunotherapy
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04728893
Haem
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (
MK-1026-003--1026-003
)
BTK inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04423029
Advanced
Phase 1
Recruiting
A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of
DF6002
as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
IL-12 Fc-fusion protein
anti-PD-1 monoclonal antibody
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04176198
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
Momelotinib
Ruxolitinib
cancer therapy
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
Myelofibrosis
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT02582697
Advanced
Phase 3
Recruiting
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12625000438459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 - Talquetamab and Teclistamab (
ZEPFHR-MM-Domain-1
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12625000429459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol (
ZEPFHR-MM
)
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000582550
Curative
Phase 2
Recruiting
Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (
WOMBAT
) - ANZUP 2201
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622000180718
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
Primary mediastinal B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001198819
Radonc
Not Applicable
Recruiting
A Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (
RESOLUTE
)
Radiotherapy
cancer therapy
Colorectal cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3677 - Wangaratta - Northeast Health Wangaratta
NCT05182931
Advanced
Phase 2
Unknown
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (
I-FIRST
Study)
BRAF V600 inhibitor
BRAF inhibitor
Dabrafenib
MEK inhibitor
RAF inhibitor
Trametinib
cancer therapy
cancer therapy,BRAF-targeting
cancer therapy,BRAF V600-targeting
cancer therapy,MEK-targeting
cancer therapy,RAF-targeting
NOT Anaplastic thyroid cancer
Thyroid cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3181 - Prahran - The Alfred Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (41)
Not yet recruiting (2)
Enrolling by invitation (1)
Unknown (1)
Recruitment Country and State
VIC (45)
NSW (40)
QLD (35)
SA (30)
WA (23)
NZ (8)
TAS (6)
ACT (2)
NT (1)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (2)
Phase 2 (16)
Phase 2 / Phase 3 (1)
Phase 3 (19)
Trial Type
Haem (19)
Advanced (18)
Curative (6)
Radonc (2)
Cancer Therapy Class
PD-1/PD-L1
22%
PD-1
18%
cereblon
11%
AR
9%
androgen axis
9%
BCMA
9%
BTK
7%
oestrogen axis
7%
proteasome
7%
Bcl2
4%
LHRH
4%
KIT
4%
PD-L1
4%
CS1
4%
GPRC5D
4%
XPO1
4%
VEGF
2%
FR-alpha
2%
FGFR3
2%
Nectin4
2%
CDK2
2%
TLR7/TLR8
2%
CD38
2%
FLT3
2%
LAG3
2%
ER
2%
DNA methyltransferase
2%
ERBB2
2%
KRAS
2%
KRAS G12C
2%
amyloid
2%
EGFR
2%
HDAC
2%
AXL
2%
CTLA4
2%
HIF2a
2%
MET
2%
RET
2%
ROS1
2%
VEGFR
2%
VEGFR2
2%
CYP17A1
2%
IL-12
2%
JAK1
2%
JAK2
2%
CD20
2%
BRAF
2%
BRAF V600
2%
MEK
2%
RAF
2%
Facility
3128 - Box Hill - Box Hill Hospital - Eastern Health (45)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (20)
5042 - Bedford Park - Flinders Medical Centre (13)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (12)
3000 - Melbourne - Peter MacCallum Cancer Centre (12)
4102 - Woolloongabba - Princess Alexandra Hospital (12)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (11)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (11)
3168 - Clayton - Monash Medical Centre (11)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (10)
2050 - Camperdown - Chris O'Brien Lifehouse (10)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (9)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (8)
3004 - Melbourne, Southbank - Alfred Health (7)
6150 - Murdoch - Fiona Stanley Hospital (7)
2170 - Liverpool - Liverpool Hospital (7)
2109 - North Ryde - Macquarie University Hospital (6)
2139 - Concord - Concord Repatriation General Hospital (6)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
3066 - Epping - Northern Hospital (6)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (5)
2076 - Wahroonga - Sydney Adventist Hospital (5)
NZ.9016 - Dunedin - Dunedin Hospital (5)
2640 - Albury - Border Medical Oncology Research Unit (5)
7000 - Hobart - Royal Hobart Hospital (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2500 - Wollongong - Wollongong Hospital (4)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
2065 - St Leonards - GenesisCare North Shore Private Hospital (4)
4575 - Birtinya - Sunshine Coast University Hospital (4)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
2217 - Kogarah - St George Hospital (4)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (4)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (4)
6009 - Nedlands - Linear Clinical Research (3)
2031 - Randwick - Prince of Wales Hospital (3)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
5112 - Elizabeth Vale - Lyell McEwin Hospital (3)
4215 - Southport - Gold Coast University Hospital (3)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
4032 - Chermside - Icon Cancer Care Chermside (2)
2605 - Garran - The Canberra Hospital (2)
3677 - Wangaratta - Northeast Health Wangaratta (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
5037 - Glandore - Ashford Cancer Centre (2)
4032 - Chermside - The Prince Charles Hospital (2)
4215 - Southport - ICON Cancer Care (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (2)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (2)
2485 - Tweed Heads - The Tweed Hospital (2)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6168 - Cooloongup - Rockingham Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4215 - Southport - Tasman Oncology (1)
NA
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
3011 - Footscray - Footscray Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3181 - Prahran - The Alfred Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Urogenital cancer
Plasma cell disorder
Multiple myeloma
Gastrointestinal cancer
Lymphoma
Non-Hodgkin's lymphoma
Colorectal cancer
Lower gastrointestinal cancer
Male genital cancers
Prostate cancer
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Leukaemia
Thoracic cancer
Gynaecological cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Myeloproliferative neoplasm
Upper gastrointestinal cancer
Ovarian cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Mantle cell lymphoma
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Myelodysplastic syndrome
Breast cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Epithelial Ovarian Cancer
Bladder cancer
Carcinoma
Melanoma
Urothelial carcinoma
Acute myeloid leukaemia
Myeloid leukaemia
Breast adenocarcinoma
HER2-positive breast cancer
Pancreatic cancer
Pancreatobiliary cancer
AL amyloidosis
Amyloidosis
Endometrial cancer
Clear cell renal cell carcinoma
Kidney cancer
Follicular lymphoma
Marginal zone lymphoma
Waldenström Macroglobulinaemia
Myelofibrosis
Germ cell tumour
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Primary mediastinal B-cell lymphoma
Hepatobiliary cancer
Hepatocellular carcinoma
Endocrine gland cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy